Systemic Lupus Erythematosus Pipeline Market Therapeutics Development Overview for H1 2017


Posted May 30, 2017 by justinebiel

Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

 
New pipeline market Systemic Lupus Erythematosus - Pipeline Review, H1 2017 adds on ReportsnReports.com. Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Systemic Lupus Erythematosus Companies are AbbVie Inc, Ablynx NV, ACEA Biosciences Inc, Actelion Ltd, AiCuris GmbH & Co KG, Amgen Inc, Argos Therapeutics Inc, Asahi Kasei Pharma Corp, Atlantic Bio Sci LLC, Aurinia Pharmaceuticals Inc, Azano Pharmaceuticals Inc, Bio-Path Holdings Inc, Biogen Inc, Biotest AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Cellular Biomedicine Group Inc, Corestem Inc more..

Order a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=1010773

Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 26, 28, 1, 44, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Discount Available at http://www.reportsnreports.com/contacts/discount.aspx?name=1010773 (This report is available at upto 25% Discount till June 02nd 2017.)

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details at [email protected] and we would be happy to help you find the business intelligence that you need. ReportsnReports.com offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By justinebiel
Country India
Categories Business , Health , Reports
Tags systemic lupus erythematosus , systemic lupus erythematosus market , systemic lupus erythematosus pipeline
Last Updated May 30, 2017